Literature DB >> 9654064

Kinetic analysis of integrin-dependent cell adhesion on vitronectin--the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides.

M Germer1, S M Kanse, T Kirkegaard, L Kjøller, B Felding-Habermann, S Goodman, K T Preissner.   

Abstract

Distinct binding interactions between cell-surface receptors and extracellular matrix components are characteristic of multifunctional adhesion proteins such as vitronectin. The close proximity of binding sites for alpha(v)-integrins and plasminogen activator inhibitor-1 (PAI-1) on vitronectin may have consequences for cell adhesion and migration, or for the localized inhibition of plasminogen activators. In this study, the kinetics and reversibility of vitronectin-dependent cell adhesion via alpha(v)-integrins was investigated using RGD peptides and PAI-1 as competitors. Active, but not latent or cleaved PAI-1, and RGD peptides were effective in preventing cell adhesion to vitronectin provided the inhibitor was present at the time of cell seeding. In a concentration-dependent manner urokinase or thrombin abrogated the inhibitory effect of PAI-1. Following cell seeding onto a vitronectin substratum, delayed addition of RGD peptides or active PAI-1 (10-20 min post-seeding) resulted in the loss of their inhibitory potential. These data were supported by experiments in a purified system where delayed addition of active PAI-1 could no longer prevent vitronectin binding to immobilized alpha(v)beta3, while a cyclic RGD peptide gave some moderate inhibition. The apparent stabilization of vitronectin-integrin contacts was observed with immobilized native or multimeric vitronectin but not with the more rigid form of denatured, aggregated multimers. These results demonstrate that the cell adhesive properties of vitronectin depend on its conformational flexibility and can be tightly regulated in a spatio-temporal manner through direct competition of cellular integrins by soluble or matrix-bound factors such as PAI-1.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9654064     DOI: 10.1046/j.1432-1327.1998.2530669.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  10 in total

1.  Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro.

Authors:  T D Brooks; J Slomp; P H Quax; A C De Bart; M T Spencer; J H Verheijen; P A Charlton
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  A phase I study of continuous infusion cilengitide in patients with solid tumors.

Authors:  Peter H O'Donnell; Samir D Undevia; Walter M Stadler; Theodore M Karrison; M Kelly Nicholas; Linda Janisch; Mark J Ratain
Journal:  Invest New Drugs       Date:  2010-09-14       Impact factor: 3.850

3.  Phosphorylation of focal adhesion kinase (FAK) on Ser732 is induced by rho-dependent kinase and is essential for proline-rich tyrosine kinase-2-mediated phosphorylation of FAK on Tyr407 in response to vascular endothelial growth factor.

Authors:  Fabrice Le Boeuf; François Houle; Mark Sussman; Jacques Huot
Journal:  Mol Biol Cell       Date:  2006-06-07       Impact factor: 4.138

4.  A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).

Authors:  L Burt Nabors; Thomas Mikkelsen; Monika E Hegi; Xiaubu Ye; Tracy Batchelor; Glenn Lesser; David Peereboom; Myrna R Rosenfeld; Jeff Olsen; Steve Brem; Joy D Fisher; Stuart A Grossman
Journal:  Cancer       Date:  2012-04-19       Impact factor: 6.860

5.  Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

Authors:  L Burt Nabors; Tom Mikkelsen; Steven S Rosenfeld; Fred Hochberg; Narasimha S Akella; Joy D Fisher; Gretchen A Cloud; Yu Zhang; Kathryn Carson; Sabine M Wittemer; A Dimitrios Colevas; Stuart A Grossman
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

Review 6.  Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.

Authors:  David A Reardon; L Burt Nabors; Roger Stupp; Tom Mikkelsen
Journal:  Expert Opin Investig Drugs       Date:  2008-08       Impact factor: 6.206

7.  Integrin alphavbeta3, requirement for VEGFR2-mediated activation of SAPK2/p38 and for Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF.

Authors:  Bénédicte Masson-Gadais; François Houle; Julie Laferrière; Jacques Huot
Journal:  Cell Stress Chaperones       Date:  2003       Impact factor: 3.667

8.  Plasminogen activator inhibitor-1 regulates the vascular expression of vitronectin.

Authors:  M Luo; Y Ji; Y Luo; R Li; W P Fay; J Wu
Journal:  J Thromb Haemost       Date:  2017-11-08       Impact factor: 5.824

9.  Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer.

Authors:  Christian Manegold; Johan Vansteenkiste; Felipe Cardenal; Wolfgang Schuette; Penella J Woll; Ernst Ulsperger; Anne Kerber; Josef Eckmayr; Joachim von Pawel
Journal:  Invest New Drugs       Date:  2012-07-03       Impact factor: 3.850

10.  Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.

Authors:  Ralf-Peter Czekay; Kathleen Aertgeerts; Scott A Curriden; David J Loskutoff
Journal:  J Cell Biol       Date:  2003-03-03       Impact factor: 10.539

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.